NEWS
DeltaStudy successfully completed
UMC Utrecht completed its DeltaStudy. 434 patients in 9 hospitals on 31 different wards were assessed for delirium and acute encephalopathy by clinical experts, EEG experts and DeltaScan.
End of intervention phase of CLEO study reached
Despite the fact that the CLEO study intervention phase largely coincided with the COVID-19 pandemic that put a tremendous strain on all hospital staff, still some 3000 patients were measured with DeltaScan, in 13 departments including renown international medical centers as UZ Leuven, Charité and Universitätsklinikum Heidelberg.
Extension of intended use for DeltaScan
Prolira is happy to announce that the intended use of DeltaScan is extended from “delirium” to “acute encephalopathy and delirium”.
CLEO Webinar on 14 December 2020
All CLEO centers were invited for an interactive webinar of an hour, ran 2x/day. Staff of nearly all centers were able to attend.
Oct 2020: All 13 participating hospital departments of CLEO study are in intervention phase!
In Oct 2020 all CLEO participants are in the Intervention phase.
EU MDR certification for Prolira!
Regulatory Milestone: Prolira has EU MDR certification!
We are proud to announce that Prolira is one of the first medical device companies in the world, to be certified according to the new EU MDR.
Prolira’s EU MDR certifiction is the result of a big team effort headed by Uschi and Rutger. We also wish to thank QAid for its full support and DARE!! Medical Certifications for the effective and constructive auditing and certification process.
For more information, click on picture above.
June 2020: CLEO study will start up again (after Corona)
After an interruption of 3 months due to the COVID-19 pandemic, the CLEO study most hospital departments were able to restart their work for the CLEO study again.
For more information, click on picture above.
March 2020: 3 more hospitals will use DeltaScan in routine care
In March 2020 a third lot of hospital departments enrolled in the intervention phase of CLEO (Clinical Evaluation Of DeltaScan)! In this phase they switch completely to using the world’s first objective device (DeltaScan), for detection and monitoring of all their patients at risk of delirium.
In the next months of 2020 all departments will switch the intervention phase.
For more information, click on picture above.
Feb 2020: 2 more hospitals use DeltaScan in routine care
In February 2020 a second lot of hospital departments enrolled in the intervention phase of CLEO (Clinical Evaluation Of DeltaScan)! In this phase they switch completely to using the world’s first objective device (DeltaScan), for detection and monitoring of all their patients at risk of delirium.
In the next months of 2020 all departments will switch the intervention phase.
For more information, click on picture above.
Prolira @ German congress “Thorax-, Heart & Vascular Surgery”on 29 Feb – 3 Mar 2020
From 29 Feb – 3 Mar 2020, Prolira and Ecumed (G) together exhibited @ the annual congress of the Deutsche Gesellschaft für Thorax-, Herz- und Gefässchirurgie in Wiesbaden, Germany. For more information, click on the picture.
Prolira B.V.
Padualaan 8
3584 CH Utrecht
The Netherlands
tel: +31 (0)6 2297 8972
info@prolira.com